Fierce Biotech May 1, 2024
With $6.5 million in seed funding, Pepper Bio has decided to shake up its portfolio by acquiring a CDK4/6 inhibitor from G1 Therapeutics.
G1 and its Chinese partner Genor Biopharma have previously touted the potential of the drug, called lerociclib, to become a “best-in-class CDK4/6 drug candidate” in the wake of phase 3 trials for HR+/HER2- metastatic breast cancer. But in its May 1 release, Pepper focused on the most common type of liver cancer, hepatocellular carcinoma (HCC).
Pepper has used its own transomics platform, dubbed COMPASS, to identify CDK4 and CDK6 as “potentially important targets” in treating HCC, the biotech explained. Preclinical testing backed up the hypothesis that lerociclib could work on this type of cancer, leading Pepper to...
Today's Sponsors
Today's Sponsor